Erasca Unveils First Clinical Candidates, Aims To Create A MAPK Clamp

SHP2, ERK Inhibitors Disclosed After Two Years, $300m In Funding

 
• By Mandy Jackson
  
staircase pathway in the beautiful forest
Erasca's first disclosed programs aim to shut down the RAS/MAPK pathway • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip